K Pharma, Inc.
4896・Growth Market・Pharmaceuticals
Business
K Pharma, Inc. is a bio-venture founded in November 2016, originating from Keio University School of Medicine, with a corporate philosophy of "realizing medical innovation and contributing to society in the medical field." The company targets central nervous system disease areas without established effective treatments, such as ALS, spinal cord injury, and dementia, hybridly developing both an iPS drug discovery business utilizing iPS cells (6 pipelines) and a regenerative medicine business (5 pipelines). It listed on the Tokyo Stock Exchange Growth Market in October 2023. At present, the company has not yet reached the stage of recording revenue, and progress in research and development serves as the main management indicator.
Business Model
The company acquires exclusive licenses to basic research results and patents from Keio University and others, advances research and development in-house, and then out-licenses rights to pharmaceutical company partners through joint research agreements or licensing agreements. Revenue takes a four-tier structure: upfront contract payments, development milestone payments, sales royalties, and sales milestone payments. KP2011 (ALS Drug Candidate) has already been out-licensed to Alfresa Pharma Corporation, which bears the development costs. In the regenerative medicine business, the company also envisions in-house manufacturing and sales over the medium to long term.
Company Strengths
Professor Hideyuki Okano (CSO) and Professor Masaya Nakamura (CTO) participate as directors, and the company has concluded multiple joint research agreements and patent licensing agreements with Keio University. In February 2023, the company established the "K Pharma-Keio Spinal Cord Regeneration Lab" within Keio University's Shinanomachi Campus, building a system to directly translate cutting-edge basic research into business operations.
In a physician-led Phase I/IIa clinical trial of ropinirole hydrochloride for ALS, a 27.9-week suppression of disease progression compared to placebo was confirmed, and the results were published in Cell Stem Cell (2023). In March 2023, the company out-licensed domestic development rights and manufacturing and marketing rights to Alfresa Pharma Corporation, and in December 2025, Alfresa Pharma completed a Phase I clinical trial of KA-2301.
The company is concurrently developing six pipelines in the iPS drug discovery business (ALS, hearing loss, frontotemporal dementia, Huntington's disease, etc.) and five pipelines in the regenerative medicine business (subacute and chronic spinal cord injury, chronic cerebral infarction, etc.). In the physician-led clinical research for subacute spinal cord injury, all four cases were included in the safety and efficacy evaluation, and the program has reached the preparation stage for transition to a corporate-sponsored clinical trial.
ENVALITH's Perspective
Performance Trend
In the cumulative first quarter of FY2026 (ending December 2026) (January to March 2026), revenue remained at zero. Due to an increase in selling, general and administrative expenses to ¥237 million (¥199 million in the same period of the previous year), the operating loss widened to ¥237 million (¥198 million in the same period of the previous year), the ordinary loss widened to ¥242 million (¥198 million in the same period of the previous year), and the quarterly net loss widened to ¥250 million (¥199 million in the same period of the previous year). The recording of bond interest expense of ¥7 million (zero in the same period of the previous year) and an impairment loss of ¥7 million recorded as an extraordinary loss also contributed to the widening of the net loss. In past results, operating profit of ¥366 million was recorded in fiscal 2023, but from fiscal 2024 onward, the company shifted into a loss phase as research and development investment increased in earnest. The full-year earnings forecast anticipates a continued substantial loss, with an operating loss of ¥1,520 million and a net loss of ¥1,616 million (net loss per share of ¥139.28).
Growth Strategy
Aiming for monetization along three axes: ALS Phase III trial, spinal cord injury physician-sponsored trial, and overseas patent acquisition
Advancing preparations jointly with Alfresa Pharma for a domestic confirmatory trial (Phase III trial). The company aims to provide the treatment to patients as soon as possible, and the start of the trial represents the most critical milestone toward approval application and license monetization.
Received a notice of allowance for a patent related to the ALS drug from the U.S. Patent and Trademark Office. This secures intellectual property that will serve as a foundation for overseas licensing-out and joint development negotiations, aiming to expand global revenue opportunities.
Based on the basic agreement concluded with Nikon Cell Innovation (February 2026), advancing technology transfer and manufacturing of investigational products. Concrete preparations toward the start of a physician-sponsored trial are progressing, which is expected to become the first monetization case in the regenerative medicine business.
Extended the joint research agreement with National Hospital Organization Osaka Medical Center to March 31, 2029, advancing concrete preparations toward a physician-sponsored trial of a regenerative medical product derived from human iPS cells. The extension reflects certain progress and results achieved, with transition to trial application being the next evaluation point.
Extended the joint research agreement with Kitasato Institute to March 2027, continuing to acquire non-clinical data and conduct efficacy evaluations using various assessment systems toward the start of clinical trials. The company aims for monetization of a third pipeline asset, following ALS and spinal cord injury.
Last updated: July 17, 2026